Drug intelligence / Profile preview

KY-0118

Development stage: Phase 1
Lead developer: Novatim Immune Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

KY-0118 is a fusion protein drug composed of a programmed cell death protein 1 (PD-1)-targeting moiety linked to an interleukin-2 (IL-2) mutein. It is designed to modulate the immune system by targeting PD-1, an immune checkpoint receptor, and delivering modified IL-2 activity. This bifunctional approach aims to stimulate anti-tumor immunity while potentially reducing immunosuppressive effects associated with native IL-2. The drug is being developed primarily for the treatment of locally advanced or metastatic solid tumors and is currently in early-phase clinical trials. The developer is Novatim Immune Therapeutics.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on KY-0118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY-0118.

Explore the full profile